The FDA updated labels for extended-release ADHD medications, warning of side effects in children under six. Although not approved for that age group, off-label use is common, with increased drug exposure and risk cited. J&J's Concerta and Novartis' Ritalin are not affected, but retail sentiment for both companies turned bearish, and parents are urged to consult doctors about risks.